Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement
R Jeffrey Neitz1, Andrei W Konradi, Hing L Sham
1Department of Medicinal Chemistry, Elan Pharmaceuticals, South San Francisco, CA 94080, United States. jeff.neitz@gmail.com
Abstract:
In this Letter, we describe the evolution of selective JNK3 inhibitors from 1, that routinely exhibit >10-fold selectivity over JNK1 and >1000-fold selectivity over related MAPKs. Strong SAR was found for substitution of the naphthalene ring, as well as for inhibitors adopting different central scaffolds. Significant potency gains were appreciated by inverting the polarity of the thione of the parent triazolothione 1, resulting in potent compounds with attractive pharmacokinetic profiles.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Inhibition of Cdk Activity
Inhibition of CDK Activity
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
cAMP-dependent Protein Kinase Pathways


